CANCER ON A CHIP

In response to the SARS-CoV-2 outbreak, Thermo Fisher Scientific has worked rapidly to develop highly affordable and accurate diagnostic solution to enable India’s clinical and public health laboratories to quickly diagnose COVID-19.

Group A Streptococcus (Group A Strep) remains fairly unchanged and is well-understood by the scientific community. However, our methods of detection have significantly improved as have various options for testing. With so many advancements in the landscape of molecular diagnostics, it is vital for all healthcare institutions to thoroughly understand and appropriately plan for common and potentially, high volume tests. In this free webinar, the featured speaker will review and explore the topic of “The Group A Strep Diagnostic Algorithm” and support a closing Q&A session. As part of his discussion, he will define and review items such as testing requirements, the disease state, prevalence in specific demographics and geographies, disease implications, the benefits and drawbacks of various testing methodologies and the testing needs of today’s variety of healthcare settings.

Manufacturing processes for gene therapy products are generally low yielding compared to production processes for other biologics.

Multicellular organisms and dynamic biological processes consist of a complex and coordinated interplay of multiple individual cells. Until recently, most molecular studies have relied on bulk analysis, combining all cells into a single average readout. In recent years, single-cell RNA sequencing technologies have enabled researchers to study development and disease at the level of individual cells, revealing cell-to-cell gene expression differences that were obscured with bulk or low throughput methods.